Q-omics provides the consensus-scored GOLGA7 profile across patient tissues and cancer cell-line models. GOLGA7 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, GOLGA7 is differentially expressed in 9, with the highest sampling consensus in HNSC. Additionally, GOLGA7 protein abundance shows 23,635 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight MESO, HNSC, and GBM as cancer lineages where GOLGA7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GOLGA7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GOLGA7 survival associations across molecular data types. GOLGA7 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (2) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GOLGA7 RNA expression–survival associations across cancer types. High GOLGA7 expression shows unfavorable associations in MESO, KIRP and LGG, but favorable associations in KIRC, HNSC and THYM. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for GOLGA7 RNA expression.
This table summarizes GOLGA7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 5. The strongest signals are observed in THCA for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for GOLGA7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GOLGA7 shows lower tumor expression in THCA and KICH and higher tumor expression in HNSC, LIHC, COAD and CHOL. The HNSC box plot shows higher GOLGA7 RNA expression in tumor versus normal tissue (log2 FC = +0.473, t-test p < 0.001).
This table shows molecular features associated with GOLGA7 in patient tissues and cancer cell lines. In patient samples, GOLGA7 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, GOLGA7 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and UPPER_AERODIGESTIVE_TRACT.
